CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗联合 ICIs 的前景与挑战
英文原题：Prospects and challenges of CAR-T cell therapy combined with ICIs.
查看英文原题
Prospects and challenges of CAR-T cell therapy combined with ICIs.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫检查点分子是一类表达于免疫细胞表面的分子，主要调节免疫稳态。嵌合抗原受体（CAR）T细胞疗法是一种免疫治疗技术，通过生物技术构建表达特定抗原受体的合成T细胞，实现靶向杀伤肿瘤。目前CAR-T 细胞疗法治疗非实体瘤已取得良好疗效，但用于实体瘤尚未达到预期效果。免疫检查点抑制剂（ICI）联合CAR-T 是一种备受期待、用于攻克实体瘤的新型联合疗法。本文综述该联合疗法治疗实体瘤所面临的挑战及其前景。
展开英文摘要原文
Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology.
Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.
论文信息
- 作者
- Lv Y、Luo X、Xie Z、Qiu J、Yang J、Deng Y、Long R、Tang G
- 单位
- The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2024
- 原文标识
- PubMed 38571495 · DOI 10.3389/fonc.2024.1368732
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →